Deficiency for MicroRNA-582 does not impact dilated cardiomyopathy or heart failure induced by pressure overload in vivo

MicroRNAs (miRNAs) are critical post-transcriptional regulators of gene expression and have been extensively implicated in cardiovascular development, homeostasis, and disease. Among them, microRNA-582 (miR-582) has been associated with several non-cardiac pathologies, yet its role in the heart remains poorly characterized despite significant cardiac expression. In this study, we investigated the functional significance of miR-582 in cardiac pathophysiology through both gain- and loss-of-function approaches. We observed differential expression of miR-582 in murine models of cardiomyopathy, prompting further mechanistic evaluation. Thus, we generated transgenic mice with cardiac-specific overexpression of miR-582 (TG-582) as well as miR-582 knockout (582-KO) mice. Neither model exhibited an obvious cardiac phenotype under basal conditions. Following pressure overload via transverse aortic constriction (TAC), both TG-582 and 582-KO mice developed hypertrophy and functional adaptations comparable to wildtype controls. Additionally, crossbreeding these models with Calsarcin-1-knockout (CS1-KO) mice, a model of dilated cardiomyopathy, did not modify the pathological phenotype. These results indicate that miR-582 does not play a determinative role in pressure overload-induced cardiac hypertrophy or in the progression of dilated cardiomyopathy. Our findings highlight the importance of rigorously controlled <i>in vivo</i> studies to accurately define the cardiac miRNA landscape and to guide future therapeutic strategies.

Authors

Institutions

Publication Details

Journal
Frontiers in Cell and Developmental Biology
Published
2025-11-10
DOI
https://doi.org/10.3389/fcell.2025.1661965
Primary Topic
MicroRNA in disease regulation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Deficiency for MicroRNA-582 does not impact dilated cardiomyopathy or heart failure induced by pressure overload in vivo

Norbert Frey, Christian Kühn, Stefano De Martini, Derk Frank et al.
Frontiers in Cell and Developmental Biology
MicroRNA in disease regulation
article

Deficiency for MicroRNA-582 does not impact dilated cardiomyopathy or heart failure induced by pressure overload in vivo

Norbert Frey, Christian Kühn, Stefano De Martini, Derk Frank, Lucia Sophie Kilian, Ashraf Yusuf Rangrez, Frauke Senger, Jakob Christoph Voran, Nesrin Schmiedel, Inka Dobberstein
article en

Abstract

MicroRNAs (miRNAs) are critical post-transcriptional regulators of gene expression and have been extensively implicated in cardiovascular development, homeostasis, and disease. Among them, microRNA-582 (miR-582) has been associated with several non-cardiac pathologies, yet its role in the heart remains poorly characterized despite significant cardiac expression. In this study, we investigated the functional significance of miR-582 in cardiac pathophysiology through both gain- and loss-of-function approaches. We observed differential expression of miR-582 in murine models of cardiomyopathy, prompting further mechanistic evaluation. Thus, we generated transgenic mice with cardiac-specific overexpression of miR-582 (TG-582) as well as miR-582 knockout (582-KO) mice. Neither model exhibited an obvious cardiac phenotype under basal conditions. Following pressure overload via transverse aortic constriction (TAC), both TG-582 and 582-KO mice developed hypertrophy and functional adaptations comparable to wildtype controls. Additionally, crossbreeding these models with Calsarcin-1-knockout (CS1-KO) mice, a model of dilated cardiomyopathy, did not modify the pathological phenotype. These results indicate that miR-582 does not play a determinative role in pressure overload-induced cardiac hypertrophy or in the progression of dilated cardiomyopathy. Our findings highlight the importance of rigorously controlled <i>in vivo</i> studies to accurately define the cardiac miRNA landscape and to guide future therapeutic strategies.

Frontiers in Cell and Developmental BiologyVol. 13
Heidelberg University (DE), Roche Pharma AG (Germany) (DE), Leibniz Institute of Environmental Medicine (DE), University Hospital Schleswig-Holstein (DE), St. Vincentius-Kliniken (DE), German Centre for Cardiovascular Research (DE), CS Diagnostics (DE), University of Lübeck (DE)
Deutsche Forschungsgemeinschaft, Christian-Albrechts-Universität zu Kiel
Openalex Percentile: Top 59%
MicroRNA in disease regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.